Biotech Business - January 19, 2022
Oasmia changes name and resolves a new issue of shares
The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights Issue is to finance the continued development of the company and its projects in accordance with its business plan and strategy, it states. Shareholders in […]
Business article - January 5, 2022
Sound Bioventures raises 110 million EUR
Sound Bioventures, a new Scandinavia-based life sciences venture capital firm, has announced the first close of its first fund. The fund has a geographic footprint on both sides of the Atlantic and will invest in European and US-based private biotech companies supporting the clinical development of novel medicines for diseases of high unmet medical need. […]
Financing - January 3, 2022
Oncorena receives 66 million SEK
Oncorena receives a capital injection of 66 million SEK from one of the company’s principal shareholders together with two new investors. Under the terms of the agreement, Oncorena can receive an additional 94 million SEK in the future. The capital will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients […]
Collaboration - December 22, 2021
Gedea receives funding for microbiome research project
Gedea Biotech has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The project goal is to better understand the microbial etiology of bacterial vaginosis (BV) and factors associated with successful, antibiotic-free […]
Financing - December 6, 2021
Omnio raises 5.5 million SEK
The company has successfully raised 5.5 million SEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers, the company states. “We are delighted with the response […]
Financing - November 15, 2021
Valo Therapeutics raises 11 million EUR
Valo Therapeutics has successfully raised 11 million EUR in an oversubscribed Pre-IPO funding round. The Pre-IPO fund included participation from existing investors, Freeman Road, and new investors, including ASX-listed MMJ Group Holdings. The total raised to date is now over Euro 22 million (around USD 25.5 million). “This successful financing is yet another significant milestone […]
